ctst0N
`
`PR Newswire
`
`lmprimis Pharmaceuticals to Offer
`Com pou nded Cyclospori ne
`Alternative to Restasis@
`lnitial prescriptions will be 99 cents for a one month supply with refills
`starting at $79 per month, including shipping
`
`rmprlmrs
`
`. .^i'. .
`
`NEWS PROVIDED BY
`lmprlmls Pharmaceutlcals,
`Oct 19,2O17, O7:3O ET
`
`lnc, {
`
`sAN DlEco, oct. 19, 2oU /PRNewswire/ -- lmprimis Pharmaceuticals, lnc. (NASD,AQ: IMMY), an ophthalmology-focused pharmaceutical company,
`today announced it is making compounded Cyclosporine-based formulations available for physicians to consider prescribing as customizable
`and potentially lower-cost alternatives to Restasis@. lmprimis'Cyclosporine-based compounded formulations, which will be packaged in a
`multi-use preservative-free bottle, are patent-pending and include "Klarity DropsrM," a patented formulation developed by renowned
`ophthalmologist Richard L. Lindstrom, MD.
`
`Dry Eye Disease is estimated to affect up to 30 million Americans and is commonly characterized by irritated, gritty, scratchy or burning eyes,
`blurred vision, and feeling particles in the eye when there are none. Advanced Dry Eye Disease may damage the front surface of the eye and
`ultimately impair vision. The lmprimis Cyclosporine-based formulations, which are made from FDA-approved drug components and
`compounded in FDA-|nspected facilities, require a patient specific prescription and may be customized according to patients' individual needs.
`
`Mark L. Baum, CEO of lmprimis stated, "We believe Dry Eye Disease patients can benefit from unique customized medications that are not
`commercially available. While physicians who use compounded Cyclosporine formulations have anecdotally known this for many years, there is
`now published data that demonstrates the clinical value of topical Cyclosporine formulations at concentrations greater than those currently
`available in commercially available medications. We are pleased to be able to offer affordable customized Cyclosporine formulations that are
`designed for patients' individual needs."
`
`Baum added, "lmprimis has long championed issues of access, affordability and competition. While there are an estimated 30 million
`Americans suffering from Dry Eye Disease, only a small fraction of these patients receive therapy. Topical Cyclosporine, which is an off-patent and
`inexpensive drug, can cost more than $5,OOO per year when it is purchased in the commercially available form of Restasis@. We believe that
`affordability can affect access to needed medications, and it is our hope that our formulations will allow more patients to gain access to a high
`qual ity customized Cyclosporine treatment option,"
`
`ln addition to this announcement, lmprimis will soon make publicly available a presentation on Surface Pharmaceuticals, lnc. Surface is a wholly
`owned subsidiary of lmprimis that is focused entirely on ocular surface disease, including Dry Eye Disease and Blepharitis. Surface has three core
`drug formulations based on two issued US patents and three pending patents, and intends to seek FDA-approval through the 5O5(b)(2) pathway
`for as many as five ocular surface disease and ophthalmic indications.
`
`ABOUT IMPRIMIS PHARMACEUTICALS
`
`lmprimis Pharmaceuticals, lnc. (NASDAQ: IMMY) is an ophthalmology-focused pharmaceutical company that produces and dispenses high
`quality innovative medications in all 50 states. lmprimis is dedicated to patient access and affordability to many critical medicines.
`Headquartered in San Diego, California, lmprimis produces and dispenses from both California and New Jersey. lmprimis is the largest
`
`4
`
`ALL 2111
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`

`

`shareholder of Eton Pharmaceuticals, lnc. (www.etonpharma.com), a company it spun out in2017. For more information about lmprimis, please
`visit the corporate website at www.lmprimisRx.com.
`
`Forward-Looking Statements
`
`.l995.
`
`This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of
`Any
`statements in this release that are not historical facts may be considered such "forward looking statements." Forward-looking statements are
`based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and
`adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those
`predicted include our ability to make commercially available our compounded formulations and technologies in a timely manner or at all;
`physician interest in prescribing our formulationsj risks related to our compounding pharmacy operations; our ability to enter into other strategic
`alliances, including arrangements with pharmacies, physicians and healthcare organizations for the development and distribution of our
`formulations; our ability to obtain intellectual property protection for our assets; our ability to accurately estimate our expenses and cash burn,
`and raise additional funds when necessary; risks related to research and development activities; the projected size of the potential market for our
`technologies and formulations; unexpected new data, safety and technical issues; regulatory and market developments impacting
`compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional
`risks and uncertainties are more fully described in lmprimis'filings with the Securities and Exchange Commission, including its,Annual Report on
`Form lO-K and its Quarterly Reports on Form lO-Q. Such documents may be read free of charge on the SEC's web site at wvwv.sec.gov. Undue
`reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law,
`lmprimis undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date
`they are made, or to reflect the occurrence of unanticipated events.
`
`Other than drugs compounded ot a registered outsourcing focility, oll lmprimis compounded formulotions moy only be prescribed pursuont
`to a physicion prescription for on individually identified potlent conslstent with federol ond stote /ows.
`
`Restasis@ and all other trademarks, service marks and trade names included or referenced in this press release, are the property of their
`respective owners.
`
`CONTACTS
`
`John Saharek
`jsaharek@imprimispharma.com
`
`a58.704.4298
`
`lnvestor Contact:
`Jon Patton
`jpatton@imprimispharma.com
`454.704.4547
`
`SOURCE lmprimis Pharmaceuticals, lnc.
`
`Related Links
`
`http://www.i m pri m isrx.com
`
`ALL 2111
`MYLAN PHARMACEUTICALS V. ALLERGAN
`IPR2016-01127, -01128, -01129, -01130, -01131 & -01132
`
`